Target Complement system

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
 
(2 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
 +
{{up|PHA Biologicals}}
 +
 
{{tp|p=32360516|t=ä. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 |pdf=|usr=}}
 
{{tp|p=32360516|t=ä. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 |pdf=|usr=}}
 
{{tp|p=32329881|t=2020. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience |pdf=|usr=}}
 
{{tp|p=32329881|t=2020. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience |pdf=|usr=}}
Zeile 5: Zeile 7:
 
{{tp|p=32495372|t=2020. Terminal complement inhibition dampens the inflammation during COVID-19.|pdf=|usr=007}}
 
{{tp|p=32495372|t=2020. Terminal complement inhibition dampens the inflammation during COVID-19.|pdf=|usr=007}}
 
{{tp|p=32417135|t=2020. Complement activation in patients with COVID-19: A novel therapeutic target.|pdf=|usr=008}}
 
{{tp|p=32417135|t=2020. Complement activation in patients with COVID-19: A novel therapeutic target.|pdf=|usr=008}}
 +
{{tp|p=32581810|t=2020. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.|pdf=|usr=011}}
 +
{{tp|p=32430402|t=2020. Could severe COVID-19 be considered a complementopathy?|pdf=|usr=009}}

Aktuelle Version vom 18. Januar 2021, 20:48 Uhr

PHA Biologicals


32360516 ä. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
32329881 2020. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience
32327719 ä. Complement as a target in COVID-19?

32271624 2020. Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis?


32495372 2020. Terminal complement inhibition dampens the inflammation during COVID-19.
32417135 2020. Complement activation in patients with COVID-19: A novel therapeutic target.
32581810 2020. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.
32430402 2020. Could severe COVID-19 be considered a complementopathy?

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis